On December 22nd, 2021, Gan & Lee Pharmaceuticals held the first online R&D day. Focusing on the R&D strategy and international business layout, the company shared the latest R&D progress, layout areas, and future strategic plans. At the same time, Gan & Lee Pharmaceuticals invited well-known experts in the field of diabetes to review the 100-years development of insulin and interpret the frontier progress in the field of diabetes treatment.

According to the 10th edition of the IDF Diabetes Atlas (IDF Diabetes Atlas), the number of adults (20-79 years old) with diabetes worldwide is expected to reach 643 million in 2030. As the first company to develop the first Chinese domestic insulin analog and produce it industrially, Gan & Lee never forgets the original aspirations. We have always shouldered the mission of providing high-quality products and services for diabetic patients around the world, and are constantly committed to improving the quality of life of diabetic patients. Gan & Lee Pharmaceuticals held a series of care activities in 2021. To support the global efforts of promoting diabetes care and prevention worldwide, Gan & Lee Pharmaceuticals has established a partnership with the International Diabetes Federation (IDF) and has become the inaugural partner of IDF to launch the WeChat official account in China, to help promote the care, prevention and treatment of diabetes. In addition, we set up columns on the company's official website and WeChat official account to popularize the history of insulin development, pay tribute to the 100th anniversary of the discovery of insulin, and help "Healthy China 2030" and achieve "Access to Diabetes Care", the vision of the world diabetes day.